多发性骨髓瘤15年无进展生存的决定因素:来自单中心的真实世界数据
该单中心真实世界研究纳入1994至2009年诊断的323例连续、未经选择的多发性骨髓瘤患者,评估15年以上长期生存与长期无进展生存的相关因素。15年与20年累积生存率分别为18%和14%,15年与20年累积无进展生存率分别为9%和7%,25例(8%)为长期无进展生存者。年轻年龄(≤65岁)、良好体能状态(ECOG PS 0-1)、低/中危分层(ISS 1或2)、无不良细胞遗传学异常、自体移植及初始治疗达完全缓解与无进展生存延长显著相关;15年时完全缓解且微小残留病阴性者末次随访均维持原疾病状态。
要点
- 323例患者15年与20年累积生存率分别为18%和14%,15年与20年累积无进展生存率分别为9%和7%。
- 25例(8%)为长期无进展生存者,15年时完全缓解且微小残留病阴性者末次随访均维持原状态。
- 年轻年龄(≤65岁)、ECOG PS 0-1、ISS 1或2、无不良细胞遗传学异常、自体移植及初始治疗达完全缓解与无进展生存延长显著相关。
核心结论
- 在接受传统化疗或第一代新型药物(沙利度胺、硼替佐米或来那度胺)治疗的患者中,约15%为长期生存者,8%在无维持治疗情况下维持长期缓解超过15年。
研究设计与样本
- 单中心真实世界研究,纳入1994至2009年诊断的323例连续、未经选择的多发性骨髓瘤患者,随访至少15年。
主要发现
- 323例患者计算的15年与20年累积生存率分别为18%和14%。
- 323例患者计算的15年与20年累积无进展生存率分别为9%和7%,25例(8%)被确定为长期无进展生存者。
- 年轻年龄(≤65岁)、良好体能状态(ECOG PS 0-1)、低/中危分层(ISS 1或2)、无不良细胞遗传学异常、自体移植及初始治疗达完全缓解与无进展生存延长显著相关。
- 15年时处于完全缓解且微小残留病阴性的所有患者,末次随访时仍维持相同疾病状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their treatment. The current study aimed to evaluate the clinical and disease characteristics of patients with very long follow-up (minimum 15 years), to identify those with very long survival (> 15 years) and those with very long disease remissions (> 15 years) after frontline treatment diagnosed at a single center from 1994 to 2009. Among 323 consecutive, unselected patients, the calculated 15-year and 20-year cumulative survival rates were 18% and 14%, respectively. Forty-nine survived for more than 15 years. Furthermore, the calculated 15-year and 20-year cumulative PFS rates for the 323 patients were 9% and 7%, respectively; 25 (8%) patients were identified as long-term progression-free survivors. Younger age (≤ 65 years), good performance status (ECOG PS 0-1), low/intermediate risk stratification (ISS 1 or 2), absence of adverse cytogenetic abnormalities, autologous transplantation and achievement of CR to initial therapy were significantly associated with prolonged PFS. Importantly, all patients who were in complete response with negative minimal residual disease at 15 years remained at the same disease status at last follow-up. In conclusion, among patients treated with either conventional chemotherapy or with first-generation novel agents (thalidomide, bortezomib, or lenalidomide), about 15% were long-term survivors and 8% remained in long-term remission for more than 15 years without maintenance treatment.
引用
- Dimopoulos MA, Ntanasis-Stathopoulos I, Fotiou D, et al. Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution. Am J Hematol. 2025. PMID: 40682251. doi:10.1002/ajh.70012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。